{"title":"Martin Danis","authors":"Sanjeet Bagcchi","doi":"10.1016/s1473-3099(25)00295-6","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00295-6","url":null,"abstract":"Eminent French physician, and expert in parasitology and mycology, died on March 12, 2025, aged 84 years.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"4 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shreya A Sreekantaswamy, Christina Topham, Laura Certain, Russell J Benefield, Lauren Madigan, Erick Maclean, Julia Curtis, John Zone, Anneli R Bowen
{"title":"Progressive centrofacial destruction due to Acanthamoeba infection from nasal rinsing","authors":"Shreya A Sreekantaswamy, Christina Topham, Laura Certain, Russell J Benefield, Lauren Madigan, Erick Maclean, Julia Curtis, John Zone, Anneli R Bowen","doi":"10.1016/s1473-3099(25)00159-8","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00159-8","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Contributors</h2>SS wrote the original draft. All authors contributed to reviewing and editing the manuscript. The authors obtained written consent from the patient's spouse for the publication of this Clinical Picture.</section></section><section><section><h2>Declarations of interests</h2>We declare no competing interests.</section></section><section><section><h2>Acknowledgments</h2>We thank the patient's family for providing consent to share the patient's case and photographs.</section></section>","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"18 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Research in brief","authors":"Priya Venkatesan","doi":"10.1016/s1473-3099(25)00302-0","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00302-0","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Broflanilide insecticide for malaria vector control</h2>In a cluster-randomised <span><span>trial</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> in a Tanzanian village, houses were sprayed once with either a new indoor residual spray (IRS) containing the meta-diamide insecticide broflanilide (844 houses) or the WHO-listed IRS Fludora Fusion (clothianidin plus deltamethrin; 916 houses). Efficacy was monitored over 12 months. The geometric mean village-level density of indoor <em>Anopheles</em> mosquitoes collected per house per night was 2·32 in the broflanilide group versus 2·87 in the control group, giving an</section></section><section><section><h2>EDP-323 antiviral for respiratory syncytial virus</h2>EDP-323, a first-in-class, oral, selective non-nucleoside inhibitor of L polymerase of respiratory syncytial virus was evaluated in a phase 1 <span><span>trial</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> in adults aged 18–65 years. Cohorts of six to eight patients were randomly assigned to receive single doses of 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, or 800 mg EDP-323, or placebo, after fasting overnight. The effect of a meal on pharmacokinetics was assessed in the 200 mg cohort. Separate cohorts of six to eight patients received multiple doses of</section></section><section><section><h2>Baloxavir for influenza transmission</h2>In a phase 3b <span><span>trial</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, researchers assessed baloxavir marboxil, an oral influenza virus endonuclease inhibitor, versus placebo in preventing influenza transmission from patients to household contacts. 1457 patients aged 5–64 years with confirmed influenza virus infection received either baloxavir (n=726) or placebo (n=731) within 48 h of symptom onset. By day 5, the adjusted relative risk of transmission as determined by PCR was 29% lower in the baloxavir group, with adjusted incidences of 9·5%</section></section><section><section><h2>Tecovirimat for mpox treatment</h2>Tecovirimat, an oral orthopoxvirus-selective antiviral developed for smallpox, was assessed for mpox treatment in a placebo-controlled <span><span>trial</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> in the Democratic Republic of the Congo. 597 patients aged a median of 10–13 years with at least one mpox s","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"135 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Who comes first: the children or the egg?","authors":"Jennifer E Schuster, Leigh M Howard","doi":"10.1016/s1473-3099(25)00183-5","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00183-5","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"30 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lauren Granskog, Kayla Saadeh, Kieran Lorenz, Joshua Quint, Tarek Salih, Timothy Lo, Kathleen Jacobson, Marisa Ramos, Eric Chapman, Robert E Snyder, Joseph A Lewnard
{"title":"Effect of JYNNEOS vaccination on mpox clinical progression: a case–control study","authors":"Lauren Granskog, Kayla Saadeh, Kieran Lorenz, Joshua Quint, Tarek Salih, Timothy Lo, Kathleen Jacobson, Marisa Ramos, Eric Chapman, Robert E Snyder, Joseph A Lewnard","doi":"10.1016/s1473-3099(25)00180-x","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00180-x","url":null,"abstract":"<h3>Background</h3>The JYNNEOS modified vaccinia virus Ankara vaccine is effective in preventing clade IIb mpox disease. However, vaccine effects on mpox severity are poorly understood. We aimed to assess associations between reported clinical characteristics and vaccination status among individuals with laboratory-confirmed mpox.<h3>Methods</h3>We conducted a case–control study using data collected from public health surveillance interviews of people with mpox in California. Eligible participants for primary analyses were men who were cisgender and participated in telephone interviews with complete responses recorded about anatomical sites where they had lesions. We estimated JYNNEOS vaccine effectiveness against progression to disease involving disseminated lesions via the adjusted odds ratio of vaccination, comparing participants who reported lesions disseminated across multiple anatomical regions (cases) with participants who reported lesions contained to a single anatomical region (controls). We used the same case–control framework to estimate vaccine effectiveness against progression to hospitalisation and prodromal symptoms.<h3>Findings</h3>Men who were cisgender represented 5763 (94·3%) of 6112 people reported to have laboratory-confrimed mpox in California from May 12, 2022, to Dec 31, 2023, among whom, 4609 (79·9%) met eligibility criteria and were included in primary analyses. Of 4609 participants, 1566 (34·0%) were classified as controls and 3043 (66·0%) were classified as cases. Among 3043 cases, 114 (3·7%) received pre-exposure vaccination and 214 (7·0%) received post-exposure vaccination only. Among 1566 controls, 285 (18·2%) received pre-exposure vaccination and 146 (9·3%) received post-exposure vaccination only. For pre-exposure vaccination, vaccine effectiveness against progression was 58·8% (95% CI 50·3–65·9); for post-exposure vaccination, vaccine effectiveness against progression was 15·9% (3·3–26·8). Pre-exposure vaccine effectiveness against progression was 66·6% (56·8–74·2) among people negative for HIV and 44·8% (27·5–58·0) for those with HIV. Pre-exposure vaccination was also associated with protection against progression to severe illness necessitating hospitalisation (85·4% [95% CI 54·3–95·3]), and with reduced odds for fever, chills, and lymphadenopathy.<h3>Interpretation</h3>Among men who were cisgender with mpox, pre-exposure vaccination with JYNNEOS was associated with less severe illness. Awareness of an attenuated disease phenotype involving localised lesions without accompanying prodromal symptoms is needed to ensure accurate diagnosis of mpox in previously vaccinated individuals.<h3>Funding</h3>The California Department of Public Health and the US National Institutes of Health.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"31 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A new era for respiratory syncytial virus infection control","authors":"","doi":"10.1016/s1473-3099(25)00310-x","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00310-x","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"74 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Vaccines and long COVID","authors":"Sanjeet Bagcchi","doi":"10.1016/s1473-3099(25)00297-x","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00297-x","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"17 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to Lancet Infect Dis 2025; 25: e345–52","authors":"","doi":"10.1016/s1473-3099(25)00304-4","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00304-4","url":null,"abstract":"<em>Chandler DJ, Davey G, Hay RJ, et al. Development of the Mycetoma Activity and Severity clinical Scale (MASS): an international Delphi study.</em> Lancet Infect Dis <em>2025; published online Feb 26. https://doi.org/10.1016/S1473-3099(24)00808-9</em>—In this Review, the end matter on The Mycetoma Activity and Severity clinical Scale (MASS) expert panel has been updated. In the Results section, the countries of the individuals recruited from Africa has been updated to Sudan, Nigeria, Mali, South Africa, and Tunisia. These corrections have been made to the online version as of May 21, 2025.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"20 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144114342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
